Literature DB >> 21240318

New drugs approved in 2009.

Erin Sears1, Sarah Brooks.   

Abstract

Year:  2010        PMID： 21240318      PMCID： PMC2848098          DOI： 10.1080/08998280.2010.11928615

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  31 in total

1.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

2.  Increased mortality after dronedarone therapy for severe heart failure.

Authors:  Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

3.  Effect of dronedarone on cardiovascular events in atrial fibrillation.

Authors:  Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

4.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

5.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

Authors:  Timothy J Craig; Robyn J Levy; Richard L Wasserman; Againdra K Bewtra; David Hurewitz; Krystyna Obtułowicz; Avner Reshef; Bruce Ritchie; Dumitru Moldovan; Todor Shirov; Vesna Grivcheva-Panovska; Peter C Kiessling; Heinz-Otto Keinecke; Jonathan A Bernstein
Journal:  J Allergy Clin Immunol       Date:  2009-09-19       Impact factor: 10.793

6.  Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.

Authors:  David A Morrow; Stephen D Wiviott; Harvey D White; Jose C Nicolau; Ezio Bramucci; Sabina A Murphy; Marc P Bonaca; Christian T Ruff; Benjamin M Scirica; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Journal:  Circulation       Date:  2009-05-18       Impact factor: 29.690

7.  Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.

Authors:  Paul Karpecki; Michael Depaolis; Judy A Hunter; Eric M White; Lee Rigel; Lynne S Brunner; Dale W Usner; Michael R Paterno; Timothy L Comstock
Journal:  Clin Ther       Date:  2009-03       Impact factor: 3.393

8.  Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

Authors:  Daniel J Clauw; Philip Mease; Robert H Palmer; R Michael Gendreau; Yong Wang
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

9.  The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Authors:  Philip J Mease; Daniel J Clauw; R Michael Gendreau; Srinivas G Rao; Jay Kranzler; Wei Chen; Robert H Palmer
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

10.  Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Authors:  E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman
Journal:  Ann Rheum Dis       Date:  2008-12-09       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.